Arbutus Biopharma Corp Shareholders' Equity
Arbutus Biopharma Corp (ABUS) had Shareholders' Equity of $258.73 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2013-12-31: Stockholders' Equity Attributable to Parent 59.19M CAD.
- 2012-12-31: Stockholders' Equity Attributable to Parent 40.92M CAD; Stockholders' Equity Attributable to Parent as first filed 40.71M CAD.
- 2011-12-31: Stockholders' Equity Attributable to Parent 5.32M CAD.
- 2010-12-31: Stockholders' Equity Attributable to Parent 10.73M CAD.
CAD
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2013-12-31 | 59.19M CAD 10-K · filed 2014-03-28 | |
| 2012-12-31 | 40.92M CAD 10-K · filed 2014-03-28 | 40.71M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 5.32M CAD 20-F · filed 2013-03-27 | |
| 2010-12-31 | 10.73M CAD 20-F · filed 2013-03-27 | |
| 2009-12-31 | 22.46M CAD 20-F · filed 2013-03-27 | |
| 2008-12-31 | 30.94M CAD 20-F · filed 2012-03-27 |
USD
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $258.73M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $260.18M 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $76.58M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $77.40M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $82.98M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $79.16M 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $97.37M 10-Q · filed 2026-08-12 | |
| 2024-09-30 | $106.89M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $122.45M 10-Q · filed 2025-11-13 | |
| 2024-03-31 | $114.64M 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $106.02M 10-K · filed 2026-03-23 | |
| 2023-09-30 | $119.34M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $134.69M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $143.91M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $136.85M 10-K · filed 2025-03-27 | |
| 2022-09-30 | $145.52M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $153.14M 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $165.84M 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $169.44M 10-K · filed 2024-03-05 | |
| 2021-09-30 | $130.14M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $100.83M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $114.15M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $101.97M 10-K · filed 2023-03-02 | |
| 2020-09-30 | $97.34M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $65.51M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $73.26M 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $72.74M 10-K · filed 2022-03-03 | |
| 2019-09-30 | $83.64M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $164.47M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $181.21M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $200.23M 10-K · filed 2021-03-04 | |
| 2018-09-30 | $215.27M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $238.07M 10-Q · filed 2019-11-06 | |
| 2018-03-31 | $232.42M 10-Q · filed 2019-11-06 | |
| 2017-12-31 | $182.47M 10-K · filed 2020-03-05 | |
| 2017-09-30 | $167.39M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $175.79M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $189.10M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $203.00M 10-K · filed 2019-03-07 | |
| 2016-09-30 | $416.63M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $431.32M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $538.08M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $547.68M 10-K · filed 2018-03-16 | |
| 2015-09-30 | $553.81M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $588.50M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $593.69M 10-Q · filed 2015-05-06 | |
| 2014-12-31 | $88.03M 10-K · filed 2018-03-16 | |
| 2014-09-30 | $95.50M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $105.14M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $105.48M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $59.19M 10-K · filed 2017-03-22 | $59.19M 6-K · filed 2014-03-06 |
| 2012-12-31 | $40.92M 10-K · filed 2016-03-09 | $40.92M 6-K · filed 2014-03-06 |
| 2011-12-31 | $5.23M 10-K · filed 2015-03-13 | $5.23M 6-K · filed 2014-03-06 |
| 2010-12-31 | $10.79M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |